Press release

Olaf Heinrich, Head Germany, is leaving the Zur Rose Group; his successor will be Walter Hess, Head Switzerland

The person responsible for the Germany segment (Head Germany) and CEO of DocMorris, Olaf Heinrich, has decided to leave the Zur Rose Group for personal reasons. He will be succeeded by Walter Hess, head of the Switzerland segment (Head Switzerland). Emanuel Lorini, head of the physicians business, will be the new responsible for the Switzerland business.

Olaf Heinrich has decided to leave the Zur Rose Group for personal reasons. He has been CEO of DocMorris since 2009 and has been responsible for the overall management of the German business since 2017. Chairman of the Board of Directors Prof. Stefan Feuerstein would like to thank Olaf Heinrich on behalf of the Board of Directors for his high level of personal dedication: "Olaf Heinrich has succeeded in promoting our growth strategy, which is particularly focused on Europe's largest market for medicines, Germany. In addition, he has made a significant contribution to positioning Zur Rose as a comprehensive healthcare provider and technology company. Today, the Group is excellently positioned to take advantage of the opportunities presented by digitalisation in the healthcare sector over the coming years. We wish Olaf Heinrich all the best for his future, both professionally and personally."

Walter Hess takes over responsibility for Germany
Walter Hess, who is responsible for the Switzerland segment, will take over the management of the Germany segment and the position as CEO of DocMorris with immediate effect. As a member of the Group Management, Walter Hess is very familiar with the online business, the strategic projects, but also with the opportunities and challenges presented in Germany. In addition, he himself headed the German subsidiary Zur Rose Pharma GmbH in Halle (Saale) for several years and previously worked as an external consultant for the Zur Rose Group in Germany. Walter Oberhänsli, Executive Director and CEO, points out: "Walter Hess has an excellent track record and is the ideal candidate for a position of such responsibility. In recent years, he managed the Swiss business very successfully and set it up for the future. We are pleased that a competent in-house successor will open up a new dimension for the Germany business over the coming years, which I'm sure will prove fascinating."

Emanuel Lorini becomes Head Switzerland and member of Group Management
Emanuel Lorini (43), head of the physicians business (B2B) since 2011 and member of the Management Board of Zur Rose Suisse AG, will assume the position of Head of the Switzerland segment. Walter Hess is very pleased about the appointment of his successor: "Under the supervision of Emanuel Lorini, the market share of the physicians business has increased significantly. In addition, he successfully pushed through a series of innovations for digitalised healthcare, which resulted in the implementation of digital services to improve medication management as well as the daily business of physicians' practices." Walter Oberhänsli adds: "Emanuel Lorini is brilliantly qualified for his new responsible role. We are very pleased to be able to fill the position in Group Management from among our own ranks." Emanuel Lorini studied business administration at the University of St. Gallen.

Investors and analyst contact
Christoph Herrmann, Head of Investor Relations
Email: , phone: 9

Media contact
Lisa Lüthi, Head of Group Communications
Email: , phone: 4

Agenda
21 January 2021 Sales 2020
18 March 2021 2020 Full-Year Results
20 April 2021 First Quarter Trading Update
29 April 2021 Annual General Meeting

Zur Rose Group

The Swiss Zur Rose Group is Europe's largest e-commerce pharmacy and one of the leading medical wholesalers in Switzerland. It also operates the leading marketplace in southern Europe for consumer health, beauty and personal care products commonly sold in pharmacies. The company is internationally present with strong brands, including Germany's best-known pharmacy brand DocMorris. Zur Rose employs more than 1,800 people at sites in Switzerland, Germany, the Netherlands, Spain and France. In 2019 it generated revenue of CHF 1,569 million (including medpex) and currently has around ten million active customers in core European markets.

With its business model, the Zur Rose Group offers high-quality, safe and cost-effective pharmaceutical care. It is also characterized by the continuous further development of digital services in the field of drug management using AI-supported applications and new technology. Zur Rose is furthermore actively driving ahead its positioning as a comprehensive provider of healthcare services. By creating a digital healthcare platform - the Zur Rose ecosystem - it networks products and digital services from qualified providers. The contribution made by Zur Rose will be to take these offerings to customers and patients and to make a relevant selection. The aim is to provide people with a seamless accompaniment and empower them to manage their own health optimally using products and digital solutions.

The shares of Zur Rose Group AG are listed on the SIX Swiss Exchange (securities number 4261528, ISIN CH0042615283, ticker ROSE). For further information please see zurrosegroup.com.